JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.

Discovery Medicine 2018 January
Since their approval by regulatory agencies worldwide, the anti-PD-1 monoclonal antibodies (mAbs), as monotherapy or in combination with ipilimumab, have become the standard frontline therapy for advanced BRAF-wild-type melanoma and an eminent rival to targeted therapy in the first-line setting for unresectable BRAF-mutated melanoma. Mature survival data from randomized phase 3 trials have emerged, confirming their position in the current treatment schema for advanced melanoma. Recently, the clinical utility of anti-PD-1 agents has extended into other disease settings, such as resected high-risk melanomas, non-cutaneous subtypes, and brain metastases. How to best combat resistance to anti-PD-1 mAbs remains the major focus of clinical investigations. This review aims to provide an update on the recent progress and current challenges relating to the clinical application of anti-PD-1 agents in the treatment of advanced melanoma.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app